The US Food and Drug Administration (USFDA) has granted approval for Wockhardt's Zaynich, a groundbreaking antibiotic designed to combat severe drug-resistant infections. This marks a significant achievement as Zaynich is the first novel antibiotic discovered and developed in India to receive such approval. According to Wockhardt's founder chairman, Habil Khorakiwala, the drug is expected to tap into a global market opportunity valued at over $1.5 billion. Zaynich combines cefepime and zidebactam, targeting multidrug-resistant superbugs and complicated urinary tract infections. With patent protection extending until 2038, the company plans to price Zaynich competitively, aligning with US treatment costs of $10,000-12,000, while offering a lower price point in India. Analyst Vishal Manchanda from Systematix noted that the global antibiotics market is around $9 billion, emphasizing the potential for Zaynich's sales to significantly contribute to this sector. Following the announcement, Wockhardt's stock experienced a notable increase, reaching a record high of ₹2,420 before closing at ₹2,152, reflecting a nearly 6% rise in value.